Syndromes such as panic disorder and somatization syndrome often respond poorly to conventional treatment with antidepressants alone. While CBT is used effectively as first-line therapy for such syndromes, it is typically used as a second-line procedure until the patient's symptoms have stabilized.
Significant differences between racial and ethnic groups in syndromic cancer prevalence and incidence suggest differing risk factors or pathogenesiologic factors. Knowledge of the annual incidence of non-syndromic malignancy and of the incidence of syndromic malignancies in specific racial or ethnic groups should enable prevention and intervention measures to be tailored to these groups.
The cause of syndrome may be similar to a symptom; however, there are no biological abnormalities that are present in all affected people. Syndromes can be secondary to many serious health problems such as cancers, multiple sclerosis, and infection. The disease hypothesis of arthritis and depression does not appear to be compatible with the syndrome concept of IBS, fibromyalgia, or functional somatic symptom disorder. It is important for clinicians to remember the need to consider all possible underlying causes of the presenting complaint.
The syndrome is the result of a complex interplay between the environment and the individual, and the syndrome is a clinical diagnosis. The syndrome is not a 'disease'. The purpose of syndrome analysis is to make a diagnosis and to develop specific plans, which should be in accordance with the individual's strengths and needs. You can find the clinical trials from the Australian Clinical Trials Register. For a good understanding of the syndrome and its treatment, you can look at the [DOPPS' clinical trials guidelines. For the treatment of chronic conditions, the [European guideline and the American guideline for state clinical trials] are good information sources.
The signs of syndrome are: obesity, infertility, low testosterone and elevated prolactin levels. Symptoms can appear soon after birth and are usually permanent. The signs and symptoms of diabetes or obesity must be differentiated from those of syndromic obesity. Syndromes such as diabetes and polycystic lipodystrophy can be diagnosed by clinical examination with a comprehensive biochemistry. Some signs can be identified in adolescence or adulthood and are the hallmark of syndromic obesity.
Syndromes are not necessarily reversible, nor do they have to be cured in order for an individual to grow and function in society. Syndromes can also bring great comfort to an individual as they help to cope with adversity and may also add color to an individual's life. Furthermore, an emphasis on diagnosis and management of syndromes, and not on curing them, can greatly assist in helping individuals overcome adversity.
Two of the four primary categories were as follows: a combination of hereditary anomalies caused by specific single-gene mutations, congenital syndromes associated with specific environmental exposures, and syndromes acquired after embryogenesis. The combination of congenital and acquired syndromes is highly indicative of their true etiology.
Symptomatic carotid artery disease has a negative impact on the quality of life even in low-risk patients. It leads to a substantial reduction in quality of life in a significant proportion of patients.
The most promising therapies for treating anosmia are in the research and development phases. Currently, there are no therapies which have been proven to treat this condition. In cases where anosmia does relate to a certain entity, such as central nervous system diseases, treatment must be guided by a neurologist in order to determine the underlying cause and choose the best available therapy. The only available treatment for anosmia with a known identifiable cause is surgical intervention, for instance a tympanoplasty or chorda tympani graft. However, in many cases, the only treatment is symptomatic and supportive. Thus, the field of anosmia research has proven difficult and continues to be highly varied.
There have been several previous, small nonrandomized trials using intravascular ultrasound. Although these studies have not been conclusive, there is a reasonable suggestion that statin therapy has a possible role in the prevention or treatment of intimal thickening. Because intravascular ultrasound has emerged as a reproducible methodology with no serious adverse events to date, multiple observational study designs are now in place by several independent groups. If the safety profile of percutaneous and surgical interventions remains positive, there seems a reasonable strategy for implementing randomized clinical trials of this technique in the near term.
[Intravascular ultrasound was used with a high percentage of patients with cardiovascular disease with other treatment modalities, including aspirin. Further research into the effects of intravascular ultrasound on cardiovascular disease is necessary.
More research is required to make an accurate estimation of how many people will be diagnosed with FHL between the ages of 5 and 45. There is no evidence suggesting that younger people will benefit from an aggressive treatment regimen sooner as opposed to later in their lives.